September 3, 2024 11:08 AM EDT
R&D

ProKid­ney ax­es one Phase 3 study, aims for 'ex­pe­dit­ed ap­proval path­way' us­ing an­oth­er

Max Bayer

Pharma Reporter

ProKid­ney be­lieves it will on­ly need one Phase 3 tri­al to win an FDA ap­proval for its kid­ney dis­ease cell ther­a­py, and will dis­con­tin­ue an­oth­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times